drugset / Trial / NCT02043821

Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker

NCT02043821

Unknown 80 enrolled Beijing Chao Yang Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Colorectal cancer patients with metastases (mCRC) at response under first-line chemotherapy are candidates for an convenient maintenance treatment.

Timeline

Start
Primary completion
2016-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1250 mg/m2 Oral

Indications